Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Archief voor de categorie ‘Productovernames’

AstraZeneca sells migraine drug for up to $302 million

AstraZeneca continued its program of divesting old medicines on Wednesday with the sale for up to $302 million of migraine drug Zomig to Germany’s Grunenthal. The British firm, which is betting on new drugs for cancer and other diseases to revive its fortunes, has sold or licensed out a raft of aging products recently.

Bron: Reuters Meer lezen »

Pfizer strikes deal with Sangamo, broadening hemophilia pipeline

U.S. drugmaker Pfizer Inc said on Wednesday it reached an agreement with Sangamo Therapeutics Inc for rights to its gene therapy programs to treat the rare blood-clotting disorder hemophilia A, under which Pfizer will pay $70 million upfront.

Bron: Reuters Meer lezen »

Mag een farmaceut de medicijnprijzen zomaar verhogen?

Medicijnen waar geen patent meer op rust, maar die nog wel van belang zijn voor sommige mensen. Geneesmiddelenfabrikanten gaan er steeds vaker mee aan de haal. Een van de middelen die sinds begin deze maand fors duurder zijn geworden is Slow K. Tot en met december 2016 was Slow K in Nederland geregistreerd door fabrikant Novartis. Daarna nam […]

Bron: Meer lezen »

Circassia strikes deal with AstraZeneca for respiratory drugs

Britain’s Circassia has secured the U.S. rights from AstraZeneca for two drugs to treat chronic obstructive pulmonary disease (COPD), a progressive lung condition affecting millions of people, for up to $230 million. Shares in Circassia jumped as much as 30 percent on Friday on news of the deal, which is its first since the failure […]

Bron: Reuters Meer lezen »

AstraZeneca licenses skin-condition drug to Leo Pharma for $115 million upfront

UK drug firm AstraZeneca (LSE: AZN) said it has licenced its drug for skin diseases to Leo Pharma for an upfront payment of $115 million. Leo Pharma will also pay AstraZeneca up to $1 billion in commercially-related milestones and up to mid-teen tiered percentage royalties on product sales, the company said in a statement.

Bron: Meer lezen »

Orexigen acquires US rights to Contrave from Takeda

Orexigen Therapeutics, Inc. and Takeda Pharmaceuticals USA, Inc, a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, have agreed to terminate the amended and restated collaboration agreement for Contrave (naltrexone HCl/bupropion HCl).

Bron: Pharma Biz Meer lezen »

Galderma acquires rights to develop and distribute Ipsen’s Dysport

Ipsen, a global specialty-driven pharmaceutical company, and Galderma, a global healthcare company focused on medical solutions in dermatology and skin health, announced that they have expanded the geographical scope of their neurotoxin partnership, whereby Galderma acquires the exclusive rights to develop, promote and distribute Dysport in the aesthetic indications in the APAC territory.

Bron: Pharma Biz Meer lezen »

GSK to buy HIV drugs from Bristol-Myers Squibb

British pharmaceutical company GlaxoSmithKline said it would buy HIV drugs at different stages of development from U.S. rival Bristol-Myers Squibb in a deal which would boost its ViiV Healthcare unit.

Bron: Reuters Meer lezen »

Valeant gets right to develop AstraZeneca’s psoriasis drug

Canada’s Valeant Pharmaceuticals International Inc said it has been granted an exclusive license by AstraZeneca Plc to develop and commercialize its late-stage experimental psoriasis drug brodalumab.

Bron: Reuters Meer lezen »

Novartis buys remaining rights to GSK treatment in deal up to $1 billion

Swiss drugmaker Novartis said on Friday it had agreed to buy all remaining rights to Ofatumumab, which is being developed for relapsing remitting multiple sclerosis and other autoimmune indications, from Britain’s GlaxoSmithKline.

Bron: Reuters Meer lezen »

« Oudere artikelen |